Trump: We May Have a Deal on Gaza
Lib Reporter Drops the Most Insane Line About Latino Kids and ICE
'Hypocrisy on Steroids': Kash Patel Torches Media Over Comey Indictment
Foreigners Who Mocked Kirk’s Death Might Soon Regret It
Alvin Bragg's Office Quietly Dismissed Charges Against Woman Who Assaulted Pro-Life Activi...
Sean Duffy Announces New Emergency Rules to Overhaul CDL Eligibility
JD Vance Demands Jimmy Kimmel Apologize to Erika Kirk Following His Return to...
Georgetown Students React to Flyers Glorifying Charlie Kirk’s Assassination
Jeffries Vows Anyone Involved in Comey Indictment 'Will Face Accountability'
Inflation Data for August Is in...
Comey Posted a Video After Indictment. Here's What He Had to Say.
Trump Announces Slew of New Tariffs
Theo Von's Objection to DHS Using Him in Video Spurs Debate
Why I Cannot Forgive Charlie Kirk's Murderer
Britain's Two-Tier Policing and Enforcement Regime Is Outrageous and Undeniable
Tipsheet

U.S. Buys 10 Million Treatment Courses of Pfizer’s COVID-19 Antiviral Pill

AP Photo/Virgina Mayo

Pharmaceutical corporation Pfizer announced on Thursday that the United States government will pay $5.29 billion for 10 million treatment courses of its experimental antiviral pill against the Wuhan coronavirus.

Advertisement

The pill, PAXLOVID, will be delivered by Pfizer beginning later this year and concluding in 2022, the company’s press release states. It notes that pricing for PAXLOVID “is based on the principles of advance commitment, volume, equity, and affordability.” Pfizer has also entered into advance purchase agreements with several other countries.

“We were thrilled with the recent results of our Phase 2/3 interim analysis, which showed overwhelming efficacy of PAXLOVID in reducing the risk of hospitalization among high-risk patients treated within three days of symptom onset by almost 90% and with no deaths, and are pleased the U.S. government recognizes this potential,” said Albert Bourla, Pfizer’s chairman and chief executive officer in a statement. “It is encouraging to see a growing understanding of the valuable role that oral investigational therapies may play in combatting [sic] COVID-19, and we look forward to continuing discussions with governments around the world to help ensure broad access for people everywhere.”

Advertisement

As I covered in September, Pfizer-BioNTech announced that they were in mid-to-late stage trails to test an oral drug designed to fight COVID-19. This month, findings from studies conducted by the company showed that PAXLOVID cut the risk of COVID-19 hospitalizations and death by 89 percent. 

In October, a New Jersey-based pharmaceutical company, Merck. Along with their partner Ridgeback Biotherapeutics, requested approval from the Food and Drug Administration (FDA) for a COVID-19 fighting pill.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement